A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia

NCT02087917 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

376

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Hypercholesterolemia

Interventions

DRUG: HS-25
DRUG: Placebo

Sponsor

Zhejiang Hisun Pharmaceutical Co. Ltd.

Collaborators

[object Object]